For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...

AstraZeneca PLC ADR closed 14.46% short of its 52-week high of $87.68, which the company reached on August 30th.

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

Understand every aspect of the global economy – and know how to make your next move.

AstraZeneca PLC closed 17.61% short of its 52-week high of £133.88, which the company reached on September 3rd.

The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.

The most recent trading session ended with Astrazeneca (AZN) standing at $73.83, reflecting a +1.12% shift from the previouse ...

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

AstraZeneca’s rare disease business, Alexion, has partnered with British health tech Pangaea Data to fund the startup’s ...

AstraZeneca (LSE:AZN) recently entered into a collaborative research initiative with IonQ, AWS, and NVIDIA, focused on ...